Denbufylline

Base Information

• Chemical Name: Denbufylline
• CAS No.: 57076-71-8
• Molecular Formula: C₁₆H₂₄N₄O₃
• Molecular Weight: 320.392
• European Community (EC) Number: 611-460-2
• UNII: 04B949KO6F
• DSSTox Substance ID: DTXSID30205687
• Nikkaji Number: J22.099J
• Wikidata: Q27164375
• NCI Thesaurus Code: C76316
• ChEMBL ID: CHEMBL277465
• Mol file: 57076-71-8.mol

Synonyms:7-(2'-oxopropyl)-1,3-di-n-butylxanthine;BRL 30892;BRL-30892;denbufylline

Chemical Property of Denbufylline

Chemical Property:

• Vapor Pressure: 1.04E-10mmHg at 25°C
• Melting Point: 98-100°C
• Boiling Point: 514.8°Cat760mmHg
• Flash Point: 265.1°C
• PSA: 78.89000
• Density: 1.23g/cm³
• LogP: 1.54890
• Storage Temp.: Refrigerator
• Solubility.: DMSO, Methanol
• XLogP3: 1.9
• Hydrogen Bond Donor Count: 0
• Hydrogen Bond Acceptor Count: 4
• Rotatable Bond Count: 8
• Exact Mass: 320.18484064
• Heavy Atom Count: 23
• Complexity: 468

Purity/Quality:

95-99% ^*data from raw suppliers

Denbufylline ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CCCCN1C2=C(C(=O)N(C1=O)CCCC)N(C=N2)CC(=O)C
• Description: Denbufylline, a xanthine derivative and PDE4 inhibitor, has effects such as vasodilatation of cerebral vessels (Willette et al., 1997) and potent activation of the hypothalamic–pituitary–adrenal axis. PDE4 is one of the cyclic adenosine monophosphate (cAMP)–specic phosphodiesterases whose tissue distribution is important in pathologies related to the central nervous and immune systems. In experimental animals, denbufylline increases adrenocorticotropic hormone (ACTH), circulating corticosterone, luteinizing hormone, corticotrophin-releasing hormone, and cAMP content of the hypothalamic tissue, but is without effect on arginine vasopressin (Kumari et al., 1997). Treves and Korczyn (1999) studied patients with AD, mixed dementia, and VaD treated with denbufylline. No signicant differences were found in comparison with placebo for the treatment of AD or VaD, although patients who received denbufylline tended to improve their cognitive scores.
• Uses: A cell permeable xanthine derivatvie that acts as a selective inhibitor of phosphodiesterase IV (PDE IV). Possesses bronchodilatory properties. Displays negative inotropic effect by acting on a verapamil-sensitive site of the calcium channel in guinea pig ventricle apaillary muscle independently of its PDE inhibitory activity. Bronchial spasmolysis agent

Technology Process of Denbufylline

There total 1 articles about Denbufylline which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield:

→ Denbufylline (57076-71-8)

Guidance literature:

Refernces

• 1、 -. "Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor". . . Retrieved 2008/06/13.